 |
|  University of Hawai'i Manoa |
|
| University of Hawai'i Manoa |
Dr. Bursell has successfully developed instrumentation to noninvasively measure different aspects of ocular physiology including retinal blood flow, retinal vascular permeability and retinal leukostasis measurements. These technologies have also been used in clinical studies, and because these methodologies are common to both clinical and basic research, can facilitate the interpretation of clinical results. He has been a significant contributor, in collaboration with Dr. King and Dr. Aiello, in the translation of the protein kinase C inhibitor from bench top to clinical trial through research showing its significant impact on retinal physiology in both animal models and preliminary clinical studies. More recently, in collaboration with Dr. Feener, he has been investigating novel vitreal proteomes such as carbonic anhydrase, and characterizing their impact on retinal physiology and retinopathy development. Over the past 20 years he has conducted, or been a part of numerous clinical research studies. He is an internationally recognized authority in his field of research.
The Comprehensive Disease Management Platform (CDMP) was developed over the last 12 years with funding from the Department of Defense lead by the Joslin Diabetes Center (PI for this was Dr. Sven-Erik Bursell now at UH Manoa) with participation from Walter Reed Medical Center, Boston VA, the Indian Health Services and Tripler Medical Center/University of Hawaii School of Medicine.
The CDMP is an open source software application that aggregates data from a variety of sources including EHR's, lab systems, and remote monitoring data from the home. It is at its core a clinical data repository with robust registry function. It provides clinical decision support, alerts and reminders as well as risk assessment engines to help prioritize management. The system also currently meets the requirement for the patient-centered medical home. It currently has unidirectional interfaces with several EHRs and is designed to accept information from any EHR.
The platform supports chronic disease management. Programs are currently being developed for multiple other diseases. It is also now licensed as open source software. This program is developed primarily with a research focus. The intention is to have an expanded user group that would direct and expand the functionality.